Society of Urologic Oncology Trials Consortium (SUO-CTC) Represents Over 200 Urology Investigative Sites

Society of Urologic Oncology Trials Consortium (SUO-CTC) Represents Over 200 Urology Investigative Sites

The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), created, owed and operated by its members, represents a clinical research investigator network over 400 members and more than 200 clinical research sites in the United States and Canada. This national alliance of leading academic and community-based uro-oncologists commits to advance further urology research. A registered not-for-profit, they form a cooperative bond with the Society of Urologic Oncology (SUO). Hence, SUO-CTC pursues clinical trials, in concern with sponsors, to investigate therapeutic interventions addressing urologic cancers including bladder cancer, prostate cancer and renal cancer.

Dedicated to Better Urology Treatments for Patients

Because many of today’s drugs, diagnostics and devices used in the treatment of urologic malignancies were developed by industry (e.g. biopharmaceutical companies), communication between urologic oncologists and the private sector is an essential element for the transfer of technology—hence creating opportunities for translating new advancements towards the care of patients with genitourinary malignancies. SUO-CTC partners with industry to offer enhanced research options for the delivery of better quality of life for urology patients.

Growing Clinical Trial Complexity

Identifying relevant urologic drug targets, not to mention the management of clinical trials, becomes an increasingly complex reality. In the past, most urology studies led by medical oncologists involved a continuous set of drugs from the National Cancer Institute (NCI) focusing on the conduct of Phase II trials based on endpoints defined by radiographic response. What a different world today! Most now are multi-disciplinary in approach and require sophisticated industry partnerships. Today’s studies mostly include serum banking and tissue collection to support the sponsor and investigators evaluate biologically based surrogate endpoints—and the patients require much longer follow-up for clinical outcome and “hard” endpoints such as survival because they are now treated with significantly lower disease burden. Logistically complex, data rich and exist in an increasingly challenging regulatory global environment, the SUO-CTC steps in and fills a vital societal need for dedicated expertise and clinical input into the design of urology focused clinical trials as well as patient recruitment.

Moreover, the SUO-CTC takes on the primary responsibility of driving clinical and translational research data to the society of Urologic Oncology not to mention the academic community at large.

Goals and Objectives

SUO-CTC seeks to encourage and coordinate clinical research in urologic oncology by formulating and performing network clinical trials involving therapeutic, diagnostic or prognostic procedures. They target cooperation and to liaise with other organizations interested in urologic oncology research as well as the ongoing support of tumor biology in urologic oncology to improvement of urologic patient health to ongoing advancement of knowledge and standards of education associated with the practice of urologic oncology. SUO-CTC includes clinical trials committees for bladder, prostate and renal cancer.


Led and managed by an independent Board of Directors which includes a President, Past President, and Secretary-Treasurer along with the President-Elect, Secretary and Treasurer of the SUO. Leadership includes the Clinical Trials Committee and members are experts in urologic cancers with organ site committees focused on bladder, prostate and renal cancers.  

The committee has been established to coordinate clinical trial activity and to identify novel therapeutic strategies with potential impact on genitourinary malignancies. Based out of their executive offices in Schaumburg, Illinois, the SUO-CTC regularly receives queries from industry and other interested parties to assist with clinical projects across the research continuum. The SUO-CTC executive management, working with the Board of Directors and Clinical Trials Committee, is structured and prepared to rapidly facilitate a number of services, including organ site specific project review and feedback, site feasibility, site recommendation, ongoing centralized communications, and member participation on advisory boards.

Project Review, Approval and Initiation Process

Are you a sponsor interested in working with SUO-CTC? First a research concept/protocol is presented to SUO-CTC member by an industry sponsor.  What is the process? First, typically a SUO-CTC member will refer a contact or industry sponsor to the SUO-CTC Director of Research Services in the central office. Thereafter, the SUO-CTC Director of Research Services secures a CDA between the Sponsor and SUO-CTC. Following execution of CDA the SUO-CTC Director of Research Services discusses with the Sponsor’s team topics such as the protocol synopsis including patient population, site requirements and accrual targets as well as scope of services available from CTC and initial assessment of services required for the project as well as the fees involved. Finally the SUO-CTC and Sponsor determine the feasibility of the collaboration and if they decide to move forward establish a timeline to proceed. The rest of the process can be read carefully in a SUO-CTC artifact titled “SUO-CTC Project Review, Approval, and Initiation Process.” 

SUO-CTC Director of Research Services

Joan M Chiaviello

Call to Action: Are you a sponsor interested in leveraging the rich and deep SUO-CTC clinical investigator network? Contact Joan M Chiaviello, RN MS Director, Clinical Research Services SUO-CTC (847) 264-5947 ; [email protected]